Invesco
PASG icon

Invesco’s Passage Bio PASG Stock Holding History

Invesco’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-688
Closed -$43K – 4114
2022
Q1 		$43K Buy
688
+12
+2% +$989 ﹤0.01% 3943
2021
Q4 		$86K Sell
676
-224
-25% -$36.6K ﹤0.01% 3921
2021
Q3 		$179K Buy
900
+123
+16% +$29.3K ﹤0.01% 3838
2021
Q2 		$205K Buy
+777
New +$240K ﹤0.01% 3780

Other funds holding PASG

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco's PASG Position: Q2 2022 in Review

Invesco sold out of Passage Bio (PASG) in Q2 2022, closing a stake of 688 shares — an estimated $43K sold.

Invesco first reported a position in PASG in Q2 2021 and held it in 4 quarters. The position peaked at $205K in Q2 2021. 85 funds tracked by Wall St. Rank hold PASG as of Q2 2022.

  • Invesco reported no remaining Passage Bio position as of Q2 2022 after selling out during the quarter.
  • Invesco sold 688 Passage Bio shares in Q2 2022, an estimated $43K.
  • Invesco first reported a position in Passage Bio in Q2 2021 and held it in 4 quarters.
  • Invesco's Passage Bio position peaked at $205K in Q2 2021.
  • 85 funds tracked by Wall St. Rank held Passage Bio as of Q2 2022.

Based on Invesco's 13F filing for Q2 2022, filed 15 Aug 2022.